BTIG initiated coverage of Praxis Precision (PRAX) with a Buy rating and $424 price target The firm, which sees a greater than $5B greenfield opportunity for ulixacaltamide in essential tremor, also notes that Praxis also has a pair of sodium channel modulators, vormatrigine and relutrigine, with positive Phase 2 data in epilepsy and developmental and epileptic encephalopathy, respectively.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Optimistic Outlook for Praxis Precision Medicines: Promising Drug Pipeline and Strategic Advancements Drive Buy Rating
- Praxis Precision price target raised to $258 from $232 at H.C. Wainwright
- Promising Growth Potential for Praxis Precision Medicines: Ulixacaltamide’s Breakthrough in Essential Tremor Treatment
- Praxis Precision participates in a conference call with H.C. Wainwright
- Praxis Precision announces inducement grants under Nasdaq lsiting rule